Did Reduced Alveolar Delivery of Surfactant Contribute to Negative Results in Adults with Acute Respiratory Distress Syndrome?
作者信息
Grotberg James B, Filoche Marcel, Willson Douglas F, Raghavendran Krishnan, Notter Robert H
机构信息
1 University of Michigan Ann Arbor, Michigan.
2 Université Paris-Est Créteil, France.
出版信息
Am J Respir Crit Care Med. 2017 Feb 15;195(4):538-540. doi: 10.1164/rccm.201607-1401LE.
Abstract
摘要
相似文献
1
Did Reduced Alveolar Delivery of Surfactant Contribute to Negative Results in Adults with Acute Respiratory Distress Syndrome?表面活性剂肺泡递送减少是否导致成人急性呼吸窘迫综合征治疗结果不佳？
Am J Respir Crit Care Med. 2017 Feb 15;195(4):538-540. doi: 10.1164/rccm.201607-1401LE.
2
Exogenous surfactant in acute respiratory distress syndrome: more is better.急性呼吸窘迫综合征中的外源性表面活性剂：越多越好。
Eur Respir J. 2002 May;19(5):787-9. doi: 10.1183/09031936.02.00284902.
3
Surfactant therapy in acute respiratory distress syndrome.
Biol Neonate. 1998 Sep;74 Suppl 1:15-20. doi: 10.1159/000047030.
4
Surfactant replacement in adults and children with ARDS--an effective therapy?成人和儿童急性呼吸窘迫综合征的表面活性剂替代治疗——一种有效的疗法？
Crit Care Nurse. 1994 Dec;14(6):54-9.
5
Surfactant: clinical applications.表面活性剂：临床应用
Am Fam Physician. 1992 Jul;46(1):233-6.
6
Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective.外源性表面活性剂治疗成人呼吸窘迫综合征？历史视角。
Thorax. 1990 Nov;45(11):825-30. doi: 10.1136/thx.45.11.825.
7
Surfactant. Evolving issues.表面活性剂。不断演变的问题。
Clin Perinatol. 1998 Mar;25(1):17-32.
8
Surfactant: current and potential therapeutic application in infants and adults.表面活性剂：在婴幼儿及成人中的当前及潜在治疗应用
J Aerosol Med. 1996 Spring;9(1):143-54. doi: 10.1089/jam.1996.9.143.
9
Perspectives for use of surfactant in children and adults.表面活性剂在儿童和成人中的应用前景。
J Matern Fetal Neonatal Med. 2004 Nov;16 Suppl 2:29-31. doi: 10.1080/14767050410001727152.
10
Pulmonary surfactant: unanswered questions.肺表面活性物质：未解决的问题。
Thorax. 1995 Apr;50(4):325-7. doi: 10.1136/thx.50.4.325.
引用本文的文献
1
Flow mechanisms of the air-blood barrier.气血屏障的流动机制。
PLoS Comput Biol. 2025 Apr 10;21(4):e1012917. doi: 10.1371/journal.pcbi.1012917. eCollection 2025 Apr.
2
Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model.新型干粉式人工合成肺表面活性剂产品治疗新生儿呼吸窘迫综合征（RDS）的研发 - 第二部分：在兔肺表面活性剂洗脱模型中的体内药效学测试。
Pharm Res. 2024 Sep;41(9):1827-1842. doi: 10.1007/s11095-024-03754-7. Epub 2024 Sep 5.
3
Pulmonary Surfactant in Adult ARDS: Current Perspectives and Future Directions.成人急性呼吸窘迫综合征中的肺表面活性物质：当前观点与未来方向
Diagnostics (Basel). 2023 Sep 15;13(18):2964. doi: 10.3390/diagnostics13182964.
4
Computational pulmonary edema: A microvascular model of alveolar capillary and interstitial flow.计算性肺水肿：肺泡毛细血管与间质流动的微血管模型
APL Bioeng. 2023 Jul 5;7(3):036101. doi: 10.1063/5.0158324. eCollection 2023 Sep.
5
Exploring pulmonary distribution of intratracheally instilled liquid foams in excised porcine lungs.研究经气管内滴注入离体猪肺内的液体泡沫的肺内分布。
Eur J Pharm Sci. 2023 Feb 1;181:106359. doi: 10.1016/j.ejps.2022.106359. Epub 2022 Dec 13.
6
Computational pulmonary edema: A microvascular model of alveolar capillary and interstitial flow.计算性肺水肿：肺泡毛细血管与间质流动的微血管模型
APL Bioeng. 2022 Nov 11;6(4):046104. doi: 10.1063/5.0109107. eCollection 2022 Dec.
7
Splitting of a three-dimensional liquid plug at an airway bifurcation.气道分支处三维液体栓的分裂。
Phys Fluids (1994). 2022 Aug;34(8):081907. doi: 10.1063/5.0101662. Epub 2022 Aug 22.
8
Computational lung modelling in respiratory medicine.计算呼吸医学中的肺部建模。
J R Soc Interface. 2022 Jun;19(191):20220062. doi: 10.1098/rsif.2022.0062. Epub 2022 Jun 8.
9
Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.表面活性物质治疗儿科和新生儿急性呼吸窘迫综合征：ESPNIC 专家对未来研究步骤的共识意见。
Crit Care. 2021 Feb 22;25(1):75. doi: 10.1186/s13054-021-03489-6.
10
Proposal of selective wedge instillation of pulmonary surfactant for COVID-19 pneumonia based on computational fluid dynamics simulation.基于计算流体动力学模拟的 COVID-19 肺炎选择性楔形肺表面活性物质灌洗术的提案。
BMC Pulm Med. 2021 Feb 22;21(1):62. doi: 10.1186/s12890-021-01435-4.
本文引用的文献
1
Three-dimensional model of surfactant replacement therapy.表面活性剂替代疗法的三维模型。
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9287-92. doi: 10.1073/pnas.1504025112. Epub 2015 Jul 13.
2
The Adult Calfactant in Acute Respiratory Distress Syndrome Trial.成人急性呼吸窘迫综合征表面活性物质试验
Chest. 2015 Aug;148(2):356-364. doi: 10.1378/chest.14-1139.
3
Pediatric calfactant in acute respiratory distress syndrome trial.儿科肺表面活性剂治疗急性呼吸窘迫综合征试验。
Pediatr Crit Care Med. 2013 Sep;14(7):657-65. doi: 10.1097/PCC.0b013e3182917b68.
4
The future of exogenous surfactant therapy.外源性表面活性剂治疗的未来。
Respir Care. 2011 Sep;56(9):1369-86; discussion 1386-8. doi: 10.4187/respcare.01306.
5
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
6
Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury.重组表面活性蛋白 C 为基础的表面活性剂治疗严重直接肺损伤患者。
Am J Respir Crit Care Med. 2011 Apr 15;183(8):1055-61. doi: 10.1164/rccm.201009-1424OC. Epub 2010 Dec 10.
7
Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.外源性表面活性剂（卡肺表面活性素）对小儿急性肺损伤的影响：一项随机对照试验。
JAMA. 2005 Jan 26;293(4):470-6. doi: 10.1001/jama.293.4.470.
8
Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.基于重组表面活性蛋白C的表面活性剂对急性呼吸窘迫综合征的影响。
N Engl J Med. 2004 Aug 26;351(9):884-92. doi: 10.1056/NEJMoa033181.
9
Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network.滴注小牛肺表面活性物质提取物（calfactant）对小儿急性低氧性呼吸衰竭有益。大西洋中部儿科重症监护网络成员。
Crit Care Med. 1999 Jan;27(1):188-95. doi: 10.1097/00003246-199901000-00050.
Zotero 插件